Book a Meeting
All Copyright 2023 share Creative Biolabs


Creative Biolabs is dedicated to solving many of the challenges in immunology projects for customers by establishing a comprehensive set of single-cell analytic platforms. Our detection platforms enable unbiased characterization of the identity and regulatory status of different classes of cells. Our analysis of Myeloid-derived suppressor cells (MDSCs) provides customers with new insights into immunosuppressive responses and ultimately lays the foundation for new markers and therapeutic approaches to improve cancer immunotherapy.

Single Cell Analysis for Myeloid Cells

Tumor-infiltrating myeloid cells are the most abundant white blood cell population in the tumor. Studies for the tumor microenvironment reveal the differentiation of immature myeloid cells into an immunosuppressive phenotype. However, little is known about the in situ dynamics of transcriptional reprogramming. Recently, scientists use single-cell RNA-seq (scRNA-seq) to explore the cellular composition and transcriptional kinetics of tumors and adjacent normal tissues in patients with early stage non-small cell lung cancer (NSCLC). They found that the myeloid cell population exhibits the most diverse changes between tumor and normal tissue, associated with tumor-mediated reprogramming.

MDSC-suppressive mechanisms. Fig.1 MDSC-suppressive mechanisms. (de Haas, 2016)

Single Cell Omics Solutions for MDSCs

Single Cell believes that understanding the underlying mechanisms of immune response is important in drug design and pharmaceutical research. The detection of the trajectory of immune cell development in healthy and pathological environments can help to determine the molecular drivers of disease and the immune escape mechanism, thus enabling people to better understand the occurrence and development of human diseases. Our single-cell detection platforms can be used to help customers study the differentiation pathways of MDSCs. MDSC is considered to be a heterogeneous population of immature myeloid cells with an immunosuppressive phenotype that is involved in the tumor escape mechanism. scRNA-seq provides a unique platform for comparing the developmental trajectories of normal and disturbed bone marrow formation to identify potential pathways that block the production and accumulation of MDSC.

  • Systematic myeloid cell reprogramming across patients

    Through single-cell sequencing technology, we can identify genes involved in reprogramming of myeloid cells. Based on changes in the expression of these genes, cell populations around the tumor can be further classified with different functions. Combining the myeloid cells of different patients and trajectory analysis can reveal the intercellular differences resulting from this stress differentiation.

  • Systematic myeloid cell reprogramming across patients. Fig.2 Systematic myeloid cell reprogramming across patients. (Song, 2019)

  • Intercellular interactions that mediate the monocyte-to-M2 differentiation

    Differentiation from monocytes to M2 macrophages prompted scientists to consider intercellular interactions in TME, such as ligand-receptor signaling. Upstream receptors associated with the transition gene can be identified. Presumed intercellular interactions are inferred from upstream receptors for monocyte differentiation to M2 and corresponding ligands expressed in other cell types.

Intercellular interactions mediate the monocyte-to-M2 differentiation. Fig.3 Intercellular interactions mediate the monocyte-to-M2 differentiation. (Song, 2019)


  • Precise algorithm for single cell analysis
  • Rich expertise in single cell multi-omics
  • Professional knowledge of immunology
  • Integrated solution based on multiple platforms

In addition to scRNA-seq analysis services, Creative Biolabs also offers other single cell analysis to facilitate your MDSC research. Moreover, we can also tailor our services to the specific requirements of our customers. If you have any questions about our single cell analysis services, please contact us to learn how we can advance your program at single-cell level.


  1. de Haas, N.; et al. Improving cancer immunotherapy by targeting the STATe of MDSCs[J]. Oncoimmunology, 2016, 5(7): e1196312.
  2. Song, Q.; et al. Dissecting intratumoral myeloid cell plasticity by single cell RNA‐seq[J]. Cancer medicine. 2019, 8(6): 3072-3085.
! ! For Research Use Only. Not for diagnostic or therapeutic purposes.